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Abstract 
Carnrot, C. 2006. Bacterial Enzymes in Thymidylate Synthesis: Molecular Characterization 
of Thymidine Kinase and Thymidylate Kinase in Ureaplasma urealyticum and Bacillus 
anthracis; Implications for antibacterial therapy. Doctor’s dissertation. 
ISSN 1652-6880, ISBN 91-576-7139-7 
 
Deoxyribonucletides (dNTPs) are synthesized via the de novo and salvage pathways. The de 
novo synthesis involves initial synthesis of ribonucleotides whereas the salvage pathway 
uses deoxyribonucleosides. Deoxynucleoside kinases (dNKs) initiate the salvage pathway 
and this step is often considered as rate limiting. The two pathways eventually coincide to 
one where nucleoside monophosphate kinases are the shared enzymes.  
 
In this thesis two thymidine kinases (TKs) and a thymidylate kinase (TMPK) are cloned, 
expressed and characterized and they originate from Ureaplasma urealyticum ( Uu) and 
Bacillus anthracis ( Ba).  Uu causes urethritis and is associated with complications in 
pregnancy, e.g. premature births, infertility, spontaneous abortions and chronic lung disease 
in the infants. Ba causes anthrax; cutaneous, inhalational and gastrointestinal, where the two 
latter have a high mortality rate. Ba is also considered as a potent bioweapon because of its 
spore forming ability. 
 
TK from Uu ( Uu-TK) was strictly pyrimidine specific and used all nucleoside 
triphosphates as phosphate donors, except dTTP that was a feedback inhibitor. Further 
studies discovered that analogs with halogen substitutions at the 5-position gave the highest 
activity. Analogs with modifications at the N3- or 3’-position showed good to moderate 
activities while 2’-substituents were not substrates. A fluorine substitution was tolerated in 
the 2’-arabinosyl position. These results correlated well with the active site structure of Uu-
TK. The Uu-TK structure contained a unique domain, the lasso domain with a structural 
zinc ion, and belonged structurally to another enzyme family than the other dNKs.  
 
TK and TMPK from Ba (Ba-TK and Ba-TMPK) were strictly pyrimidine and thymidylate 
specific, respectively. Ba-TK used all nucleoside triphosphates as phosphate donors, except 
dTTP, and phosphorylated several nucleoside analogs. The analog activities of Ba-TK were 
similar to that of Uu-TK.  Ba-TMPK used ATP and dATP as phosphate donors and a 
number of analogs as substrates. FMAUMP (1-(2-deoxy-2-fluoro-D-arabinofuranosyl)-5-
methyluracil-5’-monophosphate) was the best substrate and its nucleoside form was a 
potent inhibitor.  
 
Enzymes in thymidylate synthesis are potential targets for antibacterial therapy and the 
studies conducted in this thesis have discovered several potential leads, which will 
contribute to future design of antibiotics.  
 
Keywords: thymidine kinase, thymidylate kinase, Ureaplasma, Bacillus anthracis, anthrax, 
nucleoside analog, Uu-TK structure 
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Abbreviations 
Enzymes 
dAK        deoxyadenosine  kinase 
dCK       deoxycytidine  kinase 
dGK        deoxyguanosine  kinase 
dNK        deoxyribonucleoside  kinase 
HSV-1 TK        Herpes Simplex virus type 1 thymidine kinase 
NDPK      nucleoside  diphosphate  kinase 
NMPK       nucleoside  monophosphate  kinase 
RNR        ribonucleotide  reductase 
TK         thymidine  kinase 
TMPK            thymidylate kinase, thymidine monophosphate kinase 
UMPK       uridylate  kinase,  uridine  monophosphate  kinase 
 
Bases, nucleosides and nucleotides 
A, Ado, dAdo     adenine, adenosine, 2’-deoxyadenosine 
C, Cyd, dCyd      cytosine, cytidine, 2’-deoxycytidine 
G, Guo, dGuo     guanine, guanosine, 2’- deoxyguanosine 
T,  dThd       thymine,  2’-deoxythymidine 
U, Urd, dUrd      uracil, uridine, 2’-deoxyuridine 
-MP, -DP, -TP     5’-mono-, 5’-di, 5’-triphosphate of nucleosides 
 
Nucleoside analogs 
A r a C           1 - D-arabinofuranosylcytosine, Cytarabine 
A r a T         1 - D-arabinofuranosylthymine 
AZT        3’-azido-2’,3’-dideoxythymidine,  Zidovudine 
d4T         2’,3’-didehydro-2’,3’-dideoxythymidine,  Stavudine 
dFdC        2’,2’-difluoro-2’-deoxycytidine,  Gemcitabine,  Gemzar 
FCPU        3’-fluoro-5-cyclopropyl-2’-deoxyuridine 
5-FdCyd     5-fluoro-2’-deoxycytidine 
5-FdUrd     5-fluoro-2’-deoxyuridine,  Floxuridine,  FUDR 
FIAU        1-(2-deoxy-2-fluoro-D-arabinofuranosyl)-5-iodouracil 
FLT       3’-fluoro-2’,3’-dideoxythymidine 
FMAU       1-(2-deoxy-2-fluoro-D-arabinofuranosyl)-5-methyluracil 
5-FU        5-fluorouracil,  Flurablastin 
-MP, -DP, -TP     5’-mono-, 5’-di, 5’-triphosphate of nucleoside analogs 
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Introduction 
Synthesis of DNA precursors 
DNA is the central inheritance of all life forms (except of some viruses which have 
RNA as gene pool instead). To synthesize and maintain DNA the building blocks, 
i.e. deoxynucleoside triphosphates (dNTPs) are needed. These DNA precursors are 
synthesized by either the de novo or the salvage pathways. In the de novo synthesis 
ribose-5’-phosphate and other small molecules such as amino acids and CO2 are 
used to synthesize ribonucleoside monophosphates (NMPs) in multiple reactions 
catalyzed by different enzymes. These NMPs will be further phosphorylated to 
ribonucleoside diphosphates (NDPs), which are then reduced by ribonucleotide 
reductase (RNR) to deoxyribonucleoside diphosphates (dNDPs). A third 
phosphorylation produces deoxyribonucleoside triphosphates (dNTPs) that are 
used in DNA replication. The de novo synthesis is primarily regulated by 
ribonucleotide reductase (RNR), an enzyme both allosterically and cell cycle 
regulated (Elledge, Zhou & Allen, 1992; Greenberg & Hilfinger, 1996; Reichard, 
1988). The end products (dNTPs) are responsible for the feedback inhibition of the 
activity of RNR (Eriksson et al., 1997), while the short half-life of one of the 
subunits of RNR (called R2) makes the enzyme S-phase regulated (Chabes & 
Thelander, 2000; Eriksson et al., 1984). However, recently an additional p53 
inducible R2 subunit of RNR (p53R2) was identified in mammals (Nakano et al., 
2000; Tanaka et al., 2000). Håkansson, Hofer & Thelander (2006) have reported 
that p53R2 is constitutively expressed in mammalian cells and that p53R2, 
together with low levels of the other subunit in RNR (R1), may be able to supply a 
basal level of dNTPs needed for DNA repair and mitochondrial DNA synthesis in 
resting or non-proliferating cells.  
 
The other pathway, the salvage synthesis occurs in all cells and complements the 
de novo synthesis. Here, deoxyribonucleosides are used as start material, 
originating from degraded DNA inside or outside the cell and there are specific 
nucleoside transporters that facilitate the uptake of free deoxyribonucleosides 
(Cass et al., 1999; Kong, Engel & Wang, 2004; Plagemann, Wohlhueter & 
Woffendin, 1988). Otherwise, the half-life of free deoxyribonucleosides outside a 
cell is very short which means that the salvage pathway acts as a recycle station. 
The first phosphorylation of deoxyribonucleosides to dNMPs is catalyzed by 
deoxyribonucleoside kinases (dNKs), which traps the deoxyribonucleosides inside 
the cells. This step is often considered as the rate-limiting step in the salvage 
pathway. Further phosphorylations towards dNTPs are carried out by different 
nucleoside monophosphate kinases (NMPKs) and a ubiquitous nucleoside 
diphosphate kinase (NDPK) (Janin et al., 2000; Van Rompay, Johansson & 
Karlsson, 2000). Recycling of free purine and pyrimidine bases is also part of the 
salvage pathway, but is not the focus of this thesis and will not be discussed 
further. A simplified overview of the nucleotide metabolism is shown in figure 1. 
 
The de novo and salvage synthesis of nucleotides exist in almost all organisms 
from humans to bacteria. Bacillus anthracis, one of the pathogenic bacteria this  10
thesis focuses on, possesses both the de novo and salvage pathways. However, the 
other bacterium in focus, the human pathogen Ureaplasma urealyticum, does not 
have the de novo synthesis of purine and pyrimidine bases and no gene for RNR 
has been identified in its genome (Glass et al., 2000). Therefore, it has to rely 
completely on the salvage pathway for production of DNA precursors. 
 
 
 
 
Figure 1. Simplified overview of the synthesis of DNA precursors. dNKs, deoxynucleoside 
kinases; NDPK, nucleoside diphosphate kinase; NMPKs, nucleoside monophosphate 
kinases; NPs, nucleoside phosphorylases; 5’-NTs, 5’-nucleotidases; PRPP, phosphoribosyl-
pyrophosphate; PRTs, phosphoribosyl-transferases; RNR, ribonucleotide reductase.  
 
Bacteria in focus 
Bacillus anthracis 
Bacillus anthracis ( B. anthracis) is a spore-forming gram-positive rod-shaped 
bacterium that causes anthrax. It belongs to the Bacillus cereus group and it is the 
only obligate pathogen within the Bacilli. The virulence of B. anthracis is mainly 
due to its two plasmids, pXO1 and pXO2. pXO1 encodes a tripartite toxin 
consisting of lethal factor (LF), edema factor (EF) and protective antigen that in 
itself is non-toxic but is responsible for transporting LF and EF into the host cell.   11 
pXO2 carries the genes for a capsule that contains the anti-phagocytic poly-D-
glutamic acid, which makes the cells resistant to ingestion by macrophages 
(Baillie, 2005). Both plasmids are required for full virulence. An example of such 
a strain is the Ames strain. In this thesis experimental work has been carried out 
with an attenuated strain for safety reasons, the Sterne strain, which only has the 
pXO1 plasmid (Spencer, 2003). 
 
There are three different kinds of anthrax; cutaneous, inhalation and the very 
rare gastrointestinal form. Spores entering through the skin or mucosa cause the 
infection. Macrophages ingest the spores but are unable to degrade them. Instead 
germination occurs into vegetative cells, followed by extracellular multiplication 
and production of capsules and toxins. The cells escape to the lymph and blood 
and fatal bacteremia follows (Mock & Fouet, 2001; Öncü, Öncü & Sakarya, 2003). 
Cutaneous anthrax is the most common form and all three forms are usually 
caused by the handling of infected animals or their products. The prognosis of 
cutaneous anthrax is good and treatment is not always necessary compared to 
inhalation and gastrointestinal anthrax, which have a mortality rate >80% (Baillie 
& Read, 2001). 
 
Because the bacterium forms spores that are heat-resistant B. anthracis is 
regarded as an attractive bioweapon. B. anthracis has been used by several nations 
and groups throughout the years and most recently in the Gulf War (Zilinskas, 
1997) and the postal attack incidents in USA after 9/11 2001. Though, the largest 
outbreak caused by inhalation anthrax, occurred by mistake in Sverdlovsk (former 
Soviet Union) after an explosion in a biological laboratory. Between 64 and 105 
people died of the disease (Spencer, 2003; Öncü, Öncü & Sakarya, 2003).  
 
The regular treatment of inhalation anthrax is antibiotics (e.g. ciprofloxacin), as 
is prophylaxis, with e.g. fluoroquinolones and doxycycline. There are also 
vaccines available as well as ongoing research on new vaccines, but they all suffer 
from problems such as associated transient side effects and relatively high expense 
of production (Baillie, 2005; Spencer, 2003). 
 
Ureaplasma urealyticum 
Ureaplasma urealyticum (parvum biovar) (Uu) is a human pathogen that colonizes 
the mucosa of the urogenital tract. Uu belongs to the class of Mollicutes, which are 
considered as the smallest known free-living organisms. Mollicutes do not have a 
cell wall but belong phylogenetically to the gram-positive bacteria (Glass, et al., 
2000; Krause & Taylor-Robinson, 1992). Ureaplasma spp. differ from other 
mollicutes in having a urease that accounts for 95% of its energy supply. The 
urease hydrolyzes urea to ammonia and CO2, which is associated with ATP 
generation (Glass, et al., 2000; Pollack, 2001).  
 
Uu is an opportunistic pathogen found in 65-80% of adults and is the most 
common cause of non-chlamydial non-gonococcal urethritis (Pollack, 2001). 
Additionally, Uu is associated with complications in relation to pregnancy such as 
preterm births, infertility, spontaneous abortions, chorioamnionitis and infections  12
in newborns (Casell et al., 1993). Pneumonia, chronic lung disease, also known as 
bronchopulmonary dysplasia, and meningitis are examples of diseases that can 
arise from Uu present in the lungs, the central nervous system or systemically in 
neonates (Hudson & Talbot, 1997; Kotecha et al., 2004; Schelonka et al., 2005). 
Numerous mechanisms have been proposed for infections induced by Uu. For 
more information about pathogenic mechanisms, see recent reviews (Skevaki & 
Kafetzis, 2003; Waites, Katz & Schelonka, 2005). 
 
Neonatal Uu infection is usually treated with erythromycin (Skevaki & Kafetzis, 
2003). However, there are ongoing discussions whether erythromycin is effective. 
Newer agents belonging to the macrolides are possible candidates in treatment of 
infected preterm infants, but more studies and treatment trials need to be 
performed before any conclusions can be drawn (Waites, Katz & Schelonka, 
2005). 
 
Enzymes in deoxyribonucleoside salvage 
Deoxyribonucleoside kinases (dNKs) 
As mentioned earlier dNKs are the enzymes catalysing the initial phosphorylation 
of deoxyribonucleosides in the salvage pathway and an overview of the pathway is 
seen in figure 2. There are different sets of dNKs in many organisms. Thymidine 
kinase (TK) is found almost universally from viruses to humans, while other dNKs 
vary in their presence in different species. In humans there are four dNKs with 
overlapping specificities; cytosolic thymidine kinase (TK1) and deoxycytidine 
kinase (dCK), and mitochondrial thymidine kinase (TK2) and deoxyguanosine 
kinase (dGK). Escherichia coli (E. coli) on the other hand has only one dNK, a TK 
(Karlström, 1970; Okazaki & Kornberg, 1964a). Another bacterium with known 
dNK genes and activities are Bacillus subtilis, that has a TK, deoxyadenosine 
deoxycytidine kinase (dAK/dCK) and a dGK (Andersen & Neuhard, 2001; 
Møllgaard, 1980). Similarly Lactobacillus acidophilus (L. acidophilus) has a TK, 
dAK/dCK and a dAK/dGK. Note that L. acidophilus has no de novo synthesis and 
therefore has to rely on its salvage enzymes for its DNA precursor synthesis (Ives 
& Ikeda, 1998). Yeast, on the otherhand, has no deoxyribonucleoside salvage 
enzymes (Cherry et al., 1998). Another example of the diversity of dNKs is shown 
in the fruit fly (Drosophila melanogaster) and the mosquito (Anopheles gambiae), 
which both have a single dNK that phosphorylates all four deoxyribonucleosides 
(Johansson et al., 1999; Knecht et al., 2003; Munch-Petersen, Piskur & 
Søndergaard, 1998).  
 
In  mycoplasmas two dNKs are present, a TK and a dAK. This thesis partly 
focuses on TK from Uu and Wang et al. (2001) have previously characterized 
dAK from Mycoplasma mycoides, subspecies mycoides small colony type. B. 
anthracis shows a slightly different pattern having a TK, a dGK-like and a 
dAK/dCK-like kinase. The TK is described in this thesis but no detailed studies 
have been done so far regarding cloning and characterization of the two latter 
enzymes. 
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dNKs often show similar substrate specificity between organisms even though 
the amino acid sequence identities are low. How can they be so dissimilar in amino 
acid sequence and still have very similar function? The answer lies in the three 
dimensional (3D) structure. The crystal structures of human dCK and dGK, dNK 
from fruit fly and TK from Herpes simplex virus all have a similar 3D-fold 
(Brown et al., 1995; Johansson et al., 2001; Sabini et al., 2003; Wild et al., 1995). 
However, the recently determined structures of human TK1 and TK from Uu 
(Welin et al., 2004) show a completely different fold from the other dNKs. Given 
these results it has been proposed to divide the dNKs into two families or groups, a 
dCK/dGK/dNK-group and a TK1-group (Sandrini & Piskur, 2005). 
 
 
 
Figure 2. Simplified overview of the salvage pathway of DNA precursors. AK, adenylate 
kinase; dCK, deoxycytidine kinase; GMPK, guanylate kinase; NDPK, nucleoside 
diphosphate kinase; NPs, nucleoside phosphorylases; 5’-NTs, 5’-nucleotidases; TK1, 
cytosolic thymidine kinase; TMPK, thymidylate kinase; TS, thymidylate synthase; UMP-
CMPK, uridylate-cytidylate kinase. In mammals there is one UMP-CMPK with dual 
specificity and in bacteria there are two separate enzymes, a UMPK and a CMPK. The 
phosphorylation of dCyd, dAdo and dGuo are made by one to three different dNKs in 
different organisms. 
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Nucleoside monophosphate kinases (NMPKs) 
NMPKs catalyze the reversible phosphorylation of nucleoside monophosphates to 
nucleoside diphosphates (figure 2). Apart from the dNKs, NMPKs both belong to 
the salvage and the de novo pathways (figure 1). Hence, NMPKs are excellent 
targets for drug design, since inhibition of NMPKs will knock out both pathways 
for DNA precursor synthesis. For example, all the NMPKs in Mycoplasma 
genitalium are essential for organism survival as demonstrated in a recent study 
using global transposon mutagenesis (Glass et al., 2006). These enzymes are 
usually base specific and less specific for the sugar. Generally, there is at least one 
enzyme for each base, with a combined UMP-CMP kinase in eukaryotes and two 
separate enzymes in prokaryotes. In humans a thymidylate kinase (TMPK), a 
UMP-CMP kinase and several adenylate and guanylate kinases are found (Ren et 
al., 2005; Van Rompay, Johansson & Karlsson, 2000). Uu and B. anthracis have 
open reading frames coding for five different NMPKs (one per base) but there are 
no publications yet about any NMPK from either bacterium. All NMPKs belong to 
the nucleoside monophosphate kinase family except the prokaryotic UMPKs that 
instead belong to the amino acid kinase family (Serina et al., 1995; 
www.sanger.ac.uk//cgi-bin/Pfam/getacc?PF00696; 11-Sep-2006).  
 
Among the diversity and variety of dNKs and NMPKs there are a few things 
they have in common that are worth special attention. First, although ATP is 
considered as the physiological phosphate donor dNKs and NMPKs are usually 
not limited in their choice of phosphate donors. Other nucleoside triphosphates can 
in some cases even be better phosphate donors in vitro as compared with ATP. 
Second, Mg
2+ is required for the reaction to take place with any kinase; and last, 
the end product, i.e. the triphosphate form of the phosphate acceptor, is usually a 
feedback inhibitor of the reaction.  
 
Nucleoside diphosphate kinase (NDPK) 
NDPK is a ubiquitous enzyme, which phosphorylates nucleoside diphosphates to 
their corresponding triphosphates. The enzyme is extraordinary in that it is 
unspecific regarding both phosphate acceptor and donor, i.e. NDPK uses the ribose 
and deoxyribose forms of both purine and pyrimidine nucleotides as substrate. 
NDPK has also been suggested to be a multifunctional protein involved in e.g. cell 
growth and differentiation and tumour metastasis in relation to signal transduction 
(Bernard et al., 2000; Kimura et al., 2000). There are several 3D structures of 
NDPK from different species (Besir et al., 2005; Chen et al., 2002; Chiadmi et al., 
1993; Dumas et al., 1992; Webb et al., 1995) and the enzyme is highly conserved 
both in the overall fold and in the active site. In humans there are eight NDPK 
genes with tissue specific expression and different subcellular localization of the 
proteins (Lacombe et al., 2000). The two major isoforms are A and B, which are 
almost 90% identical (Gilles et al., 1991), whereas bacteria have one single gene 
(e.g. B. anthracis). No ndk gene has been found in the genome of Uu (Glass, et al., 
2000) and other glycolytic enzymes have been suggested to play a role in 
nucleotide synthesis (Pollack et al., 2002).  
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The work in this thesis concerns only the first two steps in the salvage pathway, 
more specifically the thymidylate synthesis, whose enzymes now will be described 
in more detail. 
 
Thymidine kinase (TK)  
TK is a well-known and widely distributed dNK. TK catalyzes the irreversible 
phosphorylation of dTMP to dTDP. Already in 1964 purification and 
characterization of TK from E. coli was published (Okazaki & Kornberg, 1964a; 
Okazaki & Kornberg, 1964b). Investigations on viral TKs followed (Carp, 1967; 
Kit, Dubbs & Anken, 1967; Klemperer et al., 1967; Littlefield & Basilico, 1966; 
Sheinin, 1966) and Herpes Simplex virus type 1 TK (HSV-1 TK) is now one of the 
most investigated TKs, largely due to its broad substrate specificity and usefulness 
in commercial drug design. HSV-1 TK belongs to the dCK/dGK/dNK family, 
which is not the focus of this thesis and will not be discussed further. For more 
information on HSV-1 TK see reviews (Fillat et al., 2003; Waldman, Haeusslein & 
Milman, 1983). TKs from poxviruses and Vaccinia virus on the other hand belong 
to the TK1 family. An alignment including Vaccinia virus is shown in figure 3 that 
illustrates the conservation of TK between organisms.  
 
Bacterial TKs 
TK from E. coli (Ec-TK) was the first and the only bacterial TK that has been 
purified and characterized. Ec-TK phosphorylated deoxythymidine (dThd), 
deoxyuridine (dUrd) and some 5’-halogenated dUrd analogs. ATP and dGTP were 
the preferred phosphate donors and dTTP was a feedback inhibitor. Nucleoside di- 
and triphosphates were activators with dCDP being the most effective one in 
stimulating the dThd phosphorylation (Okazaki & Kornberg, 1964a; Okazaki & 
Kornberg, 1964b). dTTP and the activators affected the subunit interaction of Ec-
TK so the enzyme changed quarternary structure to a higher molecular weight. 
This change also made Ec-TK less sensitive for temperature changes regarding 
enzyme activity (Iwatsuki & Okazaki, 1967a; Iwatsuki & Okazaki, 1967b). In 
addition to these early studies, there are a couple of screening studies of TK 
activities in microorganisms (Saito & Tomioka, 1984; Saito, Tomioka & Ohkido, 
1985), which illustrate a wide distribution of TK in different bacteria. Microbial 
genome sequencing projects now reveal that many bacteria species possess a tdk 
gene and table 1 summarizes the presence of the tdk gene in known bacterial 
genomes. Most classes of bacteria contain genera that have a tdk gene even if there 
are more genera in total that do not posess the gene. The variability of gene 
presence between the classes and orders is high and phylogenetic relationships, 
natural environment, host factors and variations in nucleotide metabolism can 
probably explain these distributions. Further biochemical studies will most likely 
provide information regarding why some bacteria have and some lack the tdk gene.  16
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Alignment of TK1 sequences from human (P04183), B. anthracis (AAT57468), E. 
coli (NP_287483.1), Vaccinia virus (AAB96503.1), Staphylococcus aureus (ABD37699) 
and  U. urealyticum (NP_078433) with secondary structure elements from human TK1 
(PDB code: 1XBT) and TK from U. urealyticum (PDB code: 2B8T) above and under the 
alignment, respectively. Dots above the alignments mark every tenth residue, human TK1 
numbering. Identical residues in all sequences are marked in red and similar residues are 
marked in yellow. The alignment was done using ClustalW and the figure was generated in 
WebESPript (v. 2.2). 
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Table 1. Presence of the tdk gene in bacteria with known genomes. 
Class of bacterium  General presence of a 
tdk gene 
Ratio of exceptions at 
genus level 
Actinobacteria No  4/20  (31) 
Bacteroidetes/Chlorobi Yes/No  3/6  (10) 
Bacillales Yes  3/8  (59) 
Chlamydiae No  0/3  (11) 
Clostridia No  3/8  (10) 
Cyanobacteria No  0/8  (19) 
Lactobacillales Yes  3/7  (28) 
Mollicutes Yes  0/3  (16) 
Spirochaetes No  1/3  (10) 
Others No  2/13  (16) 
Proteobacteria (phylum) 
 to  class 
 class 
 
No 
 
9/72 (124) 
    Order of bacterium in the  class    
    Enterobacteriales  Yes  3/9 (33) 
    Pasteurellales  Yes  1/4 (7) 
    Pseudomonadales  No  0/2 (12) 
    Vibrionales  Yes  0/2 (13) 
    Xanthomonadales  Yes/No  1/2 (8) 
    Others  No  7/26 (32) 
Source: TIGR CMR database (http://cmr.tigr.org/tigr-scripts/CMR/shared/Annotation 
Search.cgi; 04-Oct-2006) and NCBI databases (www.ncbi.nlm.nih.gov/sutils/genom_ 
table.cgi; 04-Oct-2006). The tdk gene was searched for as keyword (“thymidine kinase”) 
in TIGR CMR and the list of all fully sequenced bacterial genomes was obtained from 
NCBI. The genus exceptions are defined as having a tdk gene when the gene is not 
generally present in the class (or order) the genus belongs to, and vice versa. The ratio is 
determined according to how many genera there are in each class (or order). The digits in 
brackets are the total number of fully sequenced genomes in the class or order. Taxonomy 
classification according to the taxonomy browser of NCBI. 
 
Human TK1 
Human TK1 (hTK1) (EC 2.7.1.21) is a cytosolic enzyme and has homologues in 
most organisms. Its gene is located on chromosome 17 (McDougall, Kucherlapati 
& Ruddle, 1973; Petty et al., 1996) and the hTK1 cDNA codes for a polypeptide 
of 234 amino acids with a molecular weight of 25.5 kDa (Bradshaw & Deininger, 
1984; Munch-Petersen et al., 1991; Sherley & Kelly, 1988). The expression of 
hTK1 is cell cycle regulated and the enzyme level is at its peak in S-phase, which 
then falls to barely detectable levels in the G1 phase (Bello, 1974; Coppock & 
Pardee, 1987; Kauffman & Kelly, 1991). hTK1 is degraded via a ubiquitin-
proteasome pathway after mitotic exit and the ubiquitin ligase complex APC/C-
Cdh1 targets hTK1 by recognizing a KEN box in the C terminal region (Ke & 
Chang, 2004; Ke et al., 2005). Detection of the hTK1 level in serum is useful in 
cancer diagnostics where cancer patients have elevated levels of hTK1 (Gronowitz 
et al., 1984; Hallek et al., 1992; Li et al., 2005; Zhang et al., 2006). In addition, 
specific hTK1 antibodies have recently been developed, which may be beneficial 
in future diagnostics and clinical use (He et al., 2000; Kuroiwa et al., 2001; Wu et 
al., 2003; Zhang et al., 2001). 
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hTK1 is strictly pyrimidine specific and phosphorylates only dThd and dUrd. In 
addition several dThd and dUrd analogs can be phosphorylated. The chemical 
structure of dThd and the numbering of the atoms ihTs shown in figure 4. Analogs 
with small modifications at the 5-position (e.g. 5-fluoro, 5-ethyl) are good 
substrates whereas with bulkier or more polar substitutions the activity decreases 
drastically (e.g. 5-propenyl, 5-bromovinyl) (Eriksson et al., 1991; Johansson & 
Eriksson, 1996; Lee & Cheng, 1976; Munch-Petersen, et al., 1991). Modifications 
at the N3-position on the base decrease the activity but still these analogs are 
reasonably good substrates for hTK1 (Al-Madhoun, Tjarks & Eriksson, 2004; 
Bandyopadhyaya et al., 2005). Analogs with 3’-substitutions on the sugar have 
different acceptability. For example, AZT (3’-azidodeoxythymidine) and FLT (3’-
fluorodeoxythymidine) show substantial activity while d4T (2’,3’-
didehydrodeoxythymidine) is a very poor substrate for hTK1 (Balzarini, 
Herdewijn & De Clercq, 1989; Furman et al., 1986; Johansson & Eriksson, 1996; 
Matthes et al., 1988). Ribosyl and arabinosyl sugars are also very poorly 
recognized by hTK1 with the exceptions of FIAU (2’-fluoro-arabinosyl-5-iodo-
deoxyuridine) and FMAU (2’-fluoro-arabinosyl-5-methyl-deoxyuridine) (Al-
Madhoun, Tjarks & Eriksson, 2004).  
 
 
 
 
Figure 4. The chemical structure of dThd or dUrd. The numbers 1’ to 5’ is used to name the 
location of modifications on the deoxyribose carbon atoms in nucleoside analogs. 2’-ara, 2’-
arabinosyl. The numbers 1 to 6 show the corresponding numbering for the atoms in the base 
moiety. dThd, R= CH3; dUrd, R= no atom group. 
 
Regarding phosphate donors hTK1 can use all nucleoside triphosphates as 
donors, except dTTP, but ATP and dATP are by far the most preferred ones 
(Eriksson et al., 2002). dTTP is a feedback inhibitor implicated in the regulation of 
the dTTP level and thereby the dNTP pool in the cell. ATP can also regulate hTK1 
activity  in vitro. In the presence of ATP hTK1 transforms from a low affinity 
dimer to a high affinity tetramer. This is a slow process and it is dependent on the 
enzyme concentration. The resulting tetrameric form of hTK1 has a 20-fold lower 
apparent Km value compared to the dimeric form, in the absence of ATP (Li et al., 
2004; Munch-Petersen, Tyrsted & Cloos, 1993; Munch-Petersen et al., 1995).  
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Thymidine monophosphate kinase (TMPK) 
TMPK catalyzes the reversible phosphorylation of dTMP to dTDP. This reaction 
is at the junction where the salvage and de novo synthesis meet. Therefore, TMPK 
can be a potential drug target since this enzyme affects both pathways in dTTP 
synthesis.  
 
Several TMPKs from different organisms have been investigated throughout the 
years, such as human, yeast, Mycobacterium tuberculosis ( M. tuberculosis), 
Streptococcus pneumoniae, E. coli, Yersinia pestis and Vaccinia virus. Figure 5 
shows an alignment of TMPKs from different organisms, which demonstrates a 
relatively low degree of amino acid conservation. Nonetheless all known TMPKs 
are dimers and share the characteristic of being pyrimidine specific and sensitive 
for substrate modifications. They also share the ability to use other phosphate 
donors than ATP (Brundiers et al., 1999; Chenal-Francisque et al., 1999; Jong & 
Campbell, 1984; Lavie et al., 1998a; Lavie et al., 1998b; Lee & Cheng, 1977; 
Munier-Lehmann et al., 2001; Petit & Koretke, 2002; Topalis et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Alignment of TMPK sequences from human (NP_036277), B. anthracis 
(YP_026316),  E. coli (AP_001724), Vaccinia virus (AAR18016), U. urealyticum 
(AAF30425) and M. tuberculosis (NP_217764) with secondary structure elements from 
human TMPK (PDB code: 1XBT) and TMPK from M. tuberculosis (PDB code: 13GU)  20
above and under the alignment, respectively. Dots above the alignments mark every tenth 
residue, human TMPK numbering. Identical residues in all sequences are marked in red and 
similar residues are marked in yellow. The alignment was done using ClustalW and the 
figure was generated in WebESPript (v. 2.2). 
 
Bacterial TMPKS 
TMPK from M. tuberculosis (Mt-TMPK) is one of the most studied TMPKs, due 
to its catalytic mechanism that is proposed to be unique among the known TMPKs 
and its potential as a drug target because of the upcoming multiresistance against 
the bacterium. A magnesium ion is supposed to compensate for a missing 
positively charged residue in the active site seen in other TMPKs, and thereby 
coordinating the phosphate acceptor (Fioravanti et al., 2003; Haouz et al., 2003; Li 
de la Sierra et al., 2001). This difference is also supposed to explain why AZTMP 
is a substrate for other TMPKs, even if sometimes poorly, and a competitive 
inhibitor with Mt-TMPK (Fioravanti et al., 2005; Munier-Lehmann, et al., 2001). 
Other studies have shown that dTMP analogs substituted at the 3’ and 2’ position 
of the ribose and at the 5-position on the base are the best leads for antibacterial 
drug development (Haouz, et al., 2003; Vanheusden et al., 2003a; Vanheusden et 
al., 2002; Vanheusden et al., 2003b). Studies with bicyclic nucleosides as 
inhibitors that are to be published this year are also promising compounds to use 
against Mt-TMPK (Van Daele et al., 2006). 
 
TMPK of E. coli (Ec), Yersinia pestis (Yp) and Streptococcus pneumoniae (Sp) 
have also been studied. Ec-TMPK was purified and characterized already in the 
1960’s, where the enzyme was found to phosphorylate dTMP, dUMP and 5-
IdUMP with ATP and dATP as the preferred phosphate donors (Nelson & Carter, 
1969).  Ec-TMPK has also been used as a comparing TMPK to the TMPK in 
question in several studies and has therefore been kinetically characterized a 
number of times (Chenal-Francisque, et al., 1999; Lavie, et al., 1998a; Munier-
Lehmann, et al., 2001; Van Daele, et al., 2006). Ec-TMPK and Yp-TMPK have 
high sequence identity (70%) and the two enzymes behave similarly regarding 
phosphate donor and acceptor specificity, except with AZTMP. Both enzymes 
have comparable Km values for AZTMP but differ significantly in Vmax values. 
The Vmax for Yp-TMPK is 1% of that of dTMP, while the corresponding value for 
Ec-TMPK is 16% (Chenal-Francisque, et al., 1999). Sp-TMPK shares the low 
substrate specificity for AZTMP with Yp-TMPK. In fact, no activity with AZTMP 
was detected in the study of Sp-TMPK (Petit & Koretke, 2002). Moreover, the 
characterization of Sp-TMPK showed that the reaction mechanism of the enzyme 
was an ordered pathway, in which ATP binding was prior to dTMP binding (Petit 
& Koretke, 2002). 
 
Human TMPK 
Human TMPK (hTMPK) (EC 2.7.4.9) is a cytosolic enzyme and was first 
described in leukemic leukocytes (Nakai et al., 1966). Its gene is located on 
chromosome 2 (GenBank
) and hTMPK consists of 212 amino acids with a 
molecular weight of 23.8 kDa (Lee & Cheng, 1977; Tamiya et al., 1989). The 
expression of hTMPK is cell cycle regulated and the enzyme is degraded in M and   21 
early G1 phase (Huang et al., 1994; Liang et al., 1995). Similar to hTK1, hTMPK 
is degraded via the same ubiquitin-proteasome pathway. hTMPK is targeted by 
either the APC/C-Cdc20 or the APC/C-Cdh1 complex, which recognize a D box or 
a KEN box, respectively, in the hTMPK sequence (Ke, et al., 2005). Ke and 
coworkers have also shown that if TMPK and TK are not degraded the dTTP pool 
increases dramatically and a dNTP pool imbalance follows. In turn, this leads to 
growth retardation and a strikingly high frequency of gene mutations. Thus, the 
degradation control of TMPK and TK is essential to maintain a balanced dNTP 
pool and to prevent genetic instability (Ke, et al., 2005). 
 
hTMPK phosphorylates only dTMP and deoxyuridine monophosphate (dUMP). 
but several dTMP and dUMP analogs can also be phosphorylated (Lavie & 
Konrad, 2004). The majority of the analogs that have been tested are modified at 
the 3’ position on the ribose and they have variable activities. d4TMP is a rather 
good substrate while FLTMP, ddTMP and AZTMP are poor ones (Ostermann et 
al., 2003). A combination of size and hydrogen bonding abilities of the 3’-
substituent, together with its effect on the sugar ring conformation determine the 
phosphorylation efficiency of the 3’-analog by hTMPK (Lavie & Konrad, 2004). 
FMAUMP has also proven to be a substrate analog for hTMPK. The D-isomer of 
FMAUMP is more efficiently phosphorylated than the L-isomer and their 
efficiencies are about 75% and 1%, respectively, in comparison with dTMP, which 
clearly reflects the discrimination of L-nucleosides by hTMPK (Hu et al., 2005). 
 
Regarding phosphate donors, hTMPK prefers ATP and dATP but can also use 
GTP and dGTP. Other (deoxy)ribonucleotide triphosphates are poor phosphate 
donors. dTTP inhibits competitively towards either ATP or dTMP and is 
considered to be a feed-back inhibitor, being the end product in dTTP synthesis 
(Lee & Cheng, 1977). 
 
Structures of thymidine kinase (TK) and thymidine 
monophosphate kinase (TMPK) 
TK 
The first structures of a TK belonging to the TK1 family were determined and 
published in collaboration with H. Eklund’s group (SLU, Uppsala, Sweden) in 
2004 and are presented in this thesis. Today, there are five solved structures in 
different complexes from three different organisms; human, Uu and Clostridium 
acetobutylicum (Birringer et al., 2005; Kosinska et al., 2005; Welin, et al., 2004; 
www.nesg.org; 13-Sep-2006). The TKs are tetramers and each monomer consists 
of a six-stranded parallel -sheet surrounded by four helices and a long flexible 
loop (figure 6). Moreover, the monomer comprises one core domain (the / 
domain) and a much smaller lasso- and zinc-containing domain. The core domain 
includes the indispensable P-loop and is similar to the ATP-binding domain in 
enzymes of the RecA-F1ATPase family. The lasso- and zinc-domain on the other 
hand does not resemble any known structural domain. The lasso covers the 
substrate binding site and is kept in place by a conserved arginine-tyrosine couple 
in two perpendicular  ribbons. In turn, four cysteines in the -ribbons coordinate  22
the zinc ion. The last of the cysteines is replaced by a histidine in Uu. Between 
these two domains the active site is formed in a cleft. The phosphate binding site 
with the P-loop is more exposed to the environment. 
 
 
( A )                   ( B )  
 
      
 
 
Figure 6. Structures of human TK1 (hTK1), PDB code: 1XBT. (A) Monomer and (B) dimer 
of hTK1, with dTTP, Mg
2+ and Zn
2+. 
 
The two hTK1 structures were solved almost simultaneously in two different 
labs. Both enzymes were truncated in their C-termini and one of them also lacked 
15 amino acids in its N-terminal. dTTP is found in the active site in both structures 
binding backwards with the triphosphates to the P-loop. Almost all interactions 
between dTTP and the lassos in the enzymes are main-chain interactions 
(Birringer, et al., 2005). Birringer, et al. (2005) assumed lysine 32 to be 
responsible for the phosphate transfer from ATP and glutamate 98 to aid in the 
catalysis by binding to the substrate. This role of the glutamate was later on 
confirmed in the Uu-TK structure in complex with dThd where the glutamate is 
hydrogen bonded and closer to the 5’-oxygen compared to when dTTP is bound 
(Kosinska, et al., 2005). The third structure complex, TK from Clostridium 
acetobutylicum, has no substrate or nucleoside moiety bound but ADP instead that 
binds in the donor site. With an empty active site the lasso becomes disordered as 
is seen in this structure (www.nesg.org; 13-Sep-2006).  
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TMPK 
Crystal structures of TMPK in different complexes have been solved from five 
organisms to date; human, yeast, E. coli,  M. tuberculosis and Staphylococcus 
aureus (S. aureus) (Kotaka et al., 2006; Lavie, et al., 1998a; Lavie, et al., 1998b; 
Li de la Sierra, et al., 2001; Ostermann et al., 2000b). TMPKs are dimers and each 
monomer is composed of eight to nine -helices surrounding a -sheet core 
consisting of five  strands (figure 7). The monomer can be divided into three 
parts; the core region, the substrate binding region and the LID region. The core 
region is the most conserved part and contains the essential P-loop that, together 
with the LID region, are involved in the phosphate donor binding. The LID region 
is a flexible stretch of residues, which upon binding of the phosphate donor closes 
down over the phosphate binding site.  
 
All TMPKs share the same overall fold but show differences in the active site. 
Lavie, et al. (1998b) have proposed a classification based on interactions at the 
phosphate binding site. Class I TMPKs, to which human and yeast belong, have a 
basic residue in the P-loop that interacts with the -phosphate of the phosphate 
donor. Class II TMPKs, where E. coli and S. aureus are members, have a glycine 
instead and additional basic residues (mostly arginines) in the LID region that 
interact with the phosphate donor. TMPK from M. tuberculosis (Mt-TMPK) is said 
to have a third binding mechanism that involves a magnesium ion, compensating 
for a missing positively charged residue in the substrate binding. In addition, the 
last residue in the P-loop (an arginine) in Mt-TMPK plays the same role in 
phosphate donor binding as the magnesium ion does in human TMPK (Fioravanti, 
et al., 2003). This classification has its origin in the phosphorylation of AZTMP. 
Human and yeast TMPKs phosphorylate AZTMP poorly while TMPK from E. 
coli only has a 2.5-fold lower phosphorylation rate with AZTMP compared to 
dTMP (Fioravanti, et al., 2003; Lavie, et al., 1998b; Lavie et al., 1997; Ostermann 
et al., 2000a). In contrast, AZTMP is a competitive inhibitor to Mt-TMPK 
(Munier-Lehmann, et al., 2001). The difference in the AZTMP phosphorylation 
efficiency between human, yeast and E. coli TMPKs has been correlated to the 
interaction of the azido group with a conserved aspartate or glutamate in the P-
loop. The aspartate in yeast and human TMPK interacts with the 3’-hydroxyl of 
dTMP in a bidentate manner. To accommodate the larger azido group in AZTMP a 
shift of the P-loop occurs. In E. coli TMPK the corresponding residue is glutamate 
that instead interacts in a side-on fashion with the 3’-hydroxyl group of dTMP. 
This difference results in an insignificant movement of the P-loop in the presence 
of the azido group (Lavie, et al., 1998b). Thus, a shift of the P-loop is clearly fatal 
for the phosphorylation capacity in the enzymes. The inhibition mechanism of Mt-
TMPK is not suggested to involve P-loop movements. Instead, the azido group 
prevents the binding of the magnesium ion (Fioravanti, et al., 2005). 
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Figure 7. Structures of TMPK from M. tuberculosis (Mt-TMPK), PDB code: 13GU. (A) 
Monomer and (B) dimer of Mt-TMPK, with dTMP and Mg
2+. 
 
Targeting enzymes in the salvage pathway 
All organisms need to replicate their genomes in order to survive and the above 
described pathways are the tools to fulfil that request. There are a number of 
studies that show the importance of functioning deoxyribonucleoside salvage. 
Mice lacking TK1 develop kidney failure (Dobrovolsky et al., 2003) and humans 
with deficiencies in mitochondrial dNKs suffer from liver or multi-systemic failure   25 
(mutated dGK) or severe myopathy (mutated TK2) (Mandel et al., 2001; Saada et 
al., 2001; Wang et al., 2005). Enzymes in the salvage pathway are also important 
from a pharmacological point of view. Drugs targeting nucleotide metabolism 
have been successfully developed against cancer and viral diseases. Most of these 
compounds are nucleoside analogs, which exhibit their efficacy after they have 
been activated by cellular enzymes (e.g. dNKs) from their proforms to their 
triphosphate forms that interfere with viral or cellular DNA synthesis (Darby, 
1994; Herdewijn, 1994). The activated nucleoside analogs usually exert their 
character by introducing DNA strand breakage or chain termination. dFdC 
(Gemcitabine, Gemzar
) and AraC (Cytarabine) are examples of powerful and 
commercialized nucleoside analogs used in cancer treatment, which cause chain 
breakage (Grant, 1998; Grindey, Hertel & Plunkett, 1990). AZT (Zidovudine) 
(Sperling, 1998), the first approved nucleoside analog against HIV, and the 
successful antiherpetic analog Acyclovir (Sheffield et al., 2003) are examples of 
chain terminators. Nucleoside analogs such as 5-fluorouracil (5-FU) and 5-
fluorodeoxyuridine (5-FdUrd), targeting thymidylate synthase, are also important 
anticancer drugs (Goldberg & Gill, 2004; Poorter, Bakker & Veenhof, 1998). 
Moreover, the level of TK1 in sera of cancer patients has been used as a diagnostic 
marker, since the higher TK1 level indicates a high degree of rapidly growing cells 
or malignancy (Gronowitz, et al., 1984; Hallek, et al., 1992; Li, et al., 2005; 
Zhang, et al., 2006). 
 
This thesis deals with two fundamental enzymes in dTTP biosynthesis: TK and 
TMPK of two pathogenic bacteria. These two enzymes are involved in both the de 
novo and salvage synthesis of dTTP and are essential for organisms to survive 
(Glass, et al., 2006; Hutchison et al., 1999; Kobayashi et al., 2003; Mushegian & 
Koonin, 1996), which means that a knockout of the enzymes would lead to cell 
death. The question is: can we or should we apply the knowledge of enzymes in 
DNA precursor synthesis to a new area - develop new agents against Bacteria?  
 
After Fleming discovered penicillin in 1929, humans had an honest chance to 
fight bacteria for the first time in history. Some years later it looked like humans 
had won the battle against bacterial infections, but the bacteria stroke back. 
Antibiotic resistance has been found ever since antibiotics were introduced to 
medical treatment but the resistance did not become a problem until the late 1970’s 
or early 1980’s. Today multi-resistant bacteria are a well-known fact and hospitals 
are struggling with outbreaks of different multi-resistant strains. Therefore, 
antibiotics with novel targets are definitely needed to combat these bacteria. The 
work in this thesis has tried to define and started to explore such targets and the 
results will hopefully be of interest for future drug design of new antibiotics, as 
well as an exhaustive knowledge basis of the three kinases in question has been 
established.  26
Present investigations 
Aim 
This thesis intends to increase our knowledge about thymidylate synthesis in two 
pathogenic bacteria; Ureaplasma urealyticum and Bacillus anthracis. More 
specifically, two thymidine kinases and one thymidine monophosphate kinase 
were molecularly characterized with focus on their substrate specificity. In 
parallel, purification of the enzymes was carried out for crystallization trials with 
the aim of solving the 3D structures. The work in this thesis also intends to 
contribute to future drug design of antibacterial agents. 
 
Results and discussion 
Methods used in the present investigations are described in detail in papers I-V in 
the appendix, and will not be described further in this section.  
 
Paper I: Molecular characterization of thymidine kinase from Ureaplasma 
urealyticum: nucleoside analogues as potent inhibitors of mycoplasma 
growth 
Ureaplasma urealyticum (Uu) is a human pathogen causing urethritis and is 
associated with complications associated with pregnancy. Mollicutes are unable to 
synthesize purines and pyrimidines de novo and therefore has to rely on their 
salvage pathway. With this background knowledge we decided to study the 
pyrimidine salvage of Uu to investigate possible targets and agents for 
antibacterial therapy against Uu.  
 
The thymidine kinase in Uu (Uu-TK) was cloned and expressed in an E. coli 
system. The protein was affinity purified in high amounts (ca 40 mg protein/L). 
Active Uu-TK was a dimer as determined by gel filtration. In contrast to human 
TK1, ATP had no effect on subunit interactions of Uu-TK.  Uu-TK, 
phosphorylated only dThd and dUrd, similar to human TK1. dThd showed 
substrate inhibition at concentrations > 20 μM while dUrd did not saturate the 
enzyme until the millimolar range. Among the pyrimidine nucleoside analogs 5-
FdUrd was the most efficient substrate. The order of relative activity of the other 
analogs was AZT > d4T > AraT. According to substrate specificity and sequence 
alignments Uu-TK was related to human TK1. Regarding phosphate donors, Uu-
TK could use all nucleoside triphosphates as donors except dTTP. Kinetic 
parameters of ATP and GTP revealed ATP to be the most efficient phosphate 
donor of the two. dTTP showed competitive inhibition towards ATP and non-
competitive inhibition towards dThd. Hence, like most end products dTTP 
feedback inhibited an enzyme earlier in the reaction chain. This broad phosphate 
donor specificity may play a role together with the narrow phosphate acceptor 
specificity in balancing the dNTP pool. Uu DNA has a high AT content (70-75%) 
and consequently needs more dATP and dTTP than dCTP and dGTP for DNA   27 
synthesis. The ability of Uu-TK to produce dTMP with, in principle any available 
nucleoside triphosphate would surely conduce to the balance of the dNTP pool. 
 
The salvage of dThd, dCyd, 5-FdUrd and 5-FU was also investigated. The levels 
of dNDPs and dNTPs were much lower than the levels of dNMPs, which would 
imply that the production to dNDPs is rate limiting. The incorporation of labelled 
dNTPs into DNA however was quite high, which may suggest that Uu DNA 
polymerase has a high affinity to dNTPs and can work at very low dNTP levels. In 
addition, growth inhibition of Uu was performed with several nucleoside analogs. 
5-FdUrd showed to be the most potent inhibitor and 5-FdCyd was at second place. 
It was shown that 5-FdCyd inhibited Uu via its deaminated product, 5-FdUMP. 
The involvement of Uu-TK and the salvage enzymes were further clarified when 
competition studies showed how addition of dThd or dUrd to the growth media 
could protect Uu from inhibition by 5-FdUrd.  
 
Paper II: Structures of thymidine kinase 1 of human and mycoplasmic 
origin 
In search for inhibitory agents selective for a specific target, such as an enzyme, an 
available structure of the target is of great help. The structure will provide 
additional information of the target that cannot be obtained solely through 
biochemical studies. Uu-TK belongs to the TK1 family and there was no known 
structure in this family of enzymes when the project on Uu-TK started. The Uu-
TK and human TK1 structures were solved in collaboration with Hans Eklund’s 
group (SLU, Uppsala, Sweden) and the purified Uu-TK was provided by me and 
hTK1 from B. Munch-Petersen’s lab (Roskilde University, Roskilde, Denmark). 
 
Uu-TK and a C-terminal truncated version of human TK1 (hTK1) were both co-
crystallized in complex with dTTP. Both structures were tetramers and each 
monomer consisted of two domains, an / domain and an unexpected small 
lasso- and zinc-containing domain. The active site was situated between these 
domains. The / domain had a central six-stranded parallel -sheet with a long 
helix and a flexible loop on one side and three shorter helices on the other side. 
The smaller domain had a long lasso loop that covered the substrate binding site 
and two perpendicular -strands that were kept in place by a zinc ion. A conserved 
arginine-tyrosine couple from the two -strands coordinated the lasso loop. The 
monomers interacted in two different ways in the tetramer that had a central 
channel lined with mainly polar and charged residues. One of the interactions was 
mainly between two long helices forming an antiparallel pair. The other way of 
interaction was between the two -sheets that were connected in an antiparallel 
manner with water molecules in between. In Uu-TK the C-terminal helix also 
interacted with a corresponding helix in an adjacent monomer in the second type 
of interaction. Of the known structures today the Uu-TK structure is the only one 
that has a visible C-terminal and thereby is the only model for C-terminal subunit 
interaction. The hTK1 structure is truncated in its C-terminus and several bacterial 
TKs have a very short C-terminal.  
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dTTP was bound in the substrate site with the triphosphates bound to the 
phosphate binding site. The base and deoxyribose of dTTP was more buried into a 
cleft between the / domain and lasso- and zinc-domain whereas the 
triphosphates were more exposed and bound solely to the / domain. The 
hydrogen bonds between dTTP and the enzyme were almost only main-chain 
bonds. 
 
The two TK structures were very similar (rmsd 1.3 Å for 155 C atoms), despite 
the low sequence identity (29%). The fold was different from other 
deoxyribonucleoside kinases (dNKs) as well. The lasso- and zinc-containing 
domain was not found in any other known protein structure and the / domain 
was also different from the dNK structures and instead similar to enzymes in the 
RecA-F1ATPase family. These structural differences between Uu-/hTK1 and other 
dNKs indicate a different evolutionary origin of the TK1 family. 
 
Paper III: Structure of the substrate complex of thymidine kinase from 
Ureaplasma urealyticum and investigations of possible drug targets for the 
enzyme 
In this paper the phosphorylation of and inhibition by several nucleoside analogs 
of Uu-TK were studied in the light of a new structure of Uu-TK in complex with 
dThd. 
 
A  Uu-TK structure was solved in complex with dThd and the structural 
differences, when dThd was bound instead of dTTP, were close to the phosphate 
binding site, where the conformation of the flexible loop was different. In the 
complex with dThd the loop was more disordered than in the one with dTTP. This 
loop was visible in only a few subunits in both complexes, indeed indicating a high 
flexibility. Glutamate 97 (Glu97) had also moved towards dThd in that complex. 
Glu97 was hydrogen bonded to the 5’-oxygen in dThd, which means that Glu97 is 
the catalytic base in the phosphoryl transfer reaction. 
 
Several nucleoside analogs were tested on Uu-TK. 5-halogenated analogs were 
good substrates and had the highest activities. The 5-position on the base tolerated 
substitutions as large as a cyclopropyl or an ethyl group and the activity was about 
half of that of dThd. With bulkier modifications the activity decreased and no 
activity was detected with a bromovinyl group. This steric hindrance correlates 
well with the hydrophobic pocket the 5-methyl group in dThd normally fits in. 
Three N3 modified analogs with alkyl substitutions were tested and they all had 
lower activity than dThd. The hydrogen bond of the N3 nitrogen to the lasso is lost 
in the analogs. Hence, a tight spacing of the lasso is probably needed for good 
phosphorylation. The 3’-hydroxyl group was also hydrogen bonded to the lasso. 
The 3’-analogs with polar substituents could still form hydrogen bonds and 
retained substantial activity whereas analogs with nonpolar groups showed very 
low activity. Analogs with 2’-modifications showed the lowest activity of all 
tested analogs. These results agree well with the tight spacing around both sides of 
the 2’-position. However, fluorine in the 2’-arabinosyl position was accepted and 
about two fifths of the activity of dThd was retained. Two of the tested analogs   29 
showed higher relative activity with Uu-TK than with hTK1, FCPU (3’-fluoro-5-
cyclopropyldUrd) and FLT. Further kinetics showed that both the analogs were 
less efficient with Uu-TK than with hTK1. Some analogs were also chosen for 
analysis as inhibitors of dThd phosphorylation. More than half of the analogs had 
had quite low IC50 values (the concentration when 50% of the activity of the 
enzyme is inhibited), but corresponding values for hTK1 were in general lower. 
Two analogs had higher values with hTK1 than with Uu-TK, but they were not 
very efficiently phosphorylated by Uu-TK. The results from this study have 
provided ideas for further development of selective Uu-TK inhibitors, to explore 
the 5-position, the 3’-position and combinations thereof. 
 
Paper IV: Evaluation of Bacillus anthracis thymidine kinase as a potential 
target for the development of antibacterial nucleoside analogs 
Bacillus anthracis (B. anthracis) causes anthrax, which in the inhalation form has 
fatal consequences. Due to its spores and high infectiousness B. anthracis may be 
a highly potent bioweapon and was lately used as such in association with 9/11 
2001 in USA. For those reasons we decided to investigate thymidine kinase in B. 
anthracis ( Ba-TK) as a target for future development of anti-anthrax agents. 
Additionally, growth inhibition of B. anthracis with selected nucleoside analogs 
was studied. 
 
Ba-TK was cloned and expressed in an E. coli system. The protein was affinity 
purified in high amounts (ca 25 mg protein/L). Active Ba-TK was a dimer as 
determined by gel filtration. Similar to Uu-TK and in contrast to hTK1, ATP had 
no effect on subunit interactions of Ba-TK. Ba-TK, phosphorylated only dThd and 
dUrd. Substrate inhibition was observed with dThd (>15 μM) but not with dUrd. 
Furthermore,  Ba-TK used all nucleoside triphosphates as donors with a clear 
preference for guanosine. Surprisingly, dTTP showed very low but still some 
activity with Ba-TK in contrast to Uu-TK and hTK1. Several nucleoside analogs 
were tested and compounds with halogen substituents at the 5-position were the 
best substrates. With bulkier modifications the activity decreased, indicating a size 
sensitivity at this position. The 3’-analogs FLT and AZT also showed good 
activity but d4T did not. These results signify a prerequisite for binding 
interactions in both the 3’- and 2’-position to retain activity of the enzyme. The 
tested N3 analogs with alkyl substituents showed similar activity with Ba-TK as 
with Uu-TK suggesting that hydrogen bonds with the N3 nitrogen are lost in the 
analogs. The substrate and analog specificity of Ba-TK resembles the specificities 
of Uu-TK and hTK1 indicating that Ba-TK has the same overall structure as the 
two other enzymes and belongs to the TK1 family. 
 
A number of nucleoside analogs and other compounds of pharmacological 
importance were chosen to study their inhibitory effect on B. anthracis growth. 
Three compounds showed an ED50 value (effective dose) less than 200 μM; 5-FU, 
5-FdUrd and N5-2OH. There was no obvious correlation between the growth 
inhibitory effect and substrate specificity of Ba-TK of these analogs. This implies 
that there could be other enzymes or targets involved in toxicity of these 
compounds.  30
Paper V: Molecular characterization of thymidylate kinase from Bacillus 
anthracis 
Thymidylate kinase (TMPK) is at the junction of the de novo and the salvage 
pathway in dTTP synthesis, which makes it an interesting and potent target for 
drug design. Thus, we decided to characterize TMPK from B. anthracis (Ba-
TMPK) with focus on its substrate specificity. The results may be used in 
development of agents against B. anthracis. 
 
Ba-TMPK was cloned and expressed in an E. coli system. The protein was 
affinity purified to the very high amount of 180 mg/L. Gel filtration revealed that 
Ba-TMPK was a dimer, as all other known TMPKs. Regarding phosphate donors, 
Ba-TMPK used ATP and dATP as efficient donors but had low affinity towards 
other nucleoside triphosphates. Ba-TMPK recognized dTMP as substrate and 
phosphorylated dUMP with a tenfold lower activity. Other phosphate acceptors 
were very poor substrates for Ba-TMPK. Hence, Ba-TMPK is strictly thymidylate 
specific. This low affinity for dUMP is found in other TMPKs as well, which may 
imply a safety mechanism of the organism to prevent eventual excess of 
dUDP/dUTP, causing replication mistakes. Some dTMP analogs were also tested 
and FMAUMP gave the best response (with three times lower efficiency compared 
to dTMP). 5-FdUMP and d4TMP were poor substrates and no activity could be 
detected with AZTMP. These results show the sensitivity of the enzyme for 5-
position substitutions but also how sensitive Ba-TMPK is for 3’-modifications. 
Fluorine as substituent in the 2’-arabinosyl position is on the other hand tolerated. 
The nucleoside forms of the above-mentioned analogs were tested as inhibitors of 
dTMP phosphorylation and the same pattern was observed, with FMAU being the 
best inhibitor. The inhibition pattern implies a surprisingly minor importance of 
the 5’-phosphate compared to the nucleoside moiety in substrate binding affinity. 
Several nucleoside analogs with rather bulky 5’-modifications designed as non-
substrate inhibitors were tested on Ba-TMPK as well. A few of the analogs 
inhibited the enzyme up to 30%. These analogs and FMAU(MP) are the most 
promising leads for future research on agents against B. anthracis. 
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Concluding remarks and future perspectives 
Three enzymes in the thymidylate synthesis have been studied in this thesis; 
thymidine kinase and thymidylate kinase from Bacillus anhracis (Ba-TK and Ba-
TMPK) and thymidine kinase from Ureaplasma urealyticum ( Uu-TK). 
Additionally, the structure of Uu-TK has been solved together with co-workers.  
 
In this thesis we have shown that the TK1 family differs both enzymatically and 
structurally from other dNKs - having a more narrow substrate specificity and a 
completely different 3D structure. The overall structure of enzymes in the TK1 
family is similar to the RecA-F1ATPase enzyme family, but TK1 enzymes also 
have a unique domain baptized to the lasso- and zinc-domain. The substrate 
specificities of the TK1 enzymes resemble one another and many of the 
interactions between the substrate and the enzyme are to the backbone of the 
protein. There are, however, minor differences in the active site between TK1 
enzymes. Furthermore, it takes a whole enzyme to do the reaction. The major part 
of the reaction outcome is of course due to the active site but other parts of the 
protein can be important just as well. In the present investigations we have taken 
the first step when looking for potential antibacterial agents and found a number of 
leads. The next step would be further exploration of those leads and investigations 
of the active site in the search for specific inhibitors.  
 
Despite the similarities in substrate specificity between TK1 enzymes they have 
different phosphorylation efficiencies. This feature has to be taken into account in 
drug design. In vitro studies of TK1 enzymes are mainly done with recombinant 
proteins, as in the case of Uu-TK and Ba-TK. The phosphorylation efficiency, the 
abundance and expression of the enzymes are not necessarily the same in vivo. 
Hence, there are many aspects that are needed to be considered. One more is the 
multiple steps involved in activating nucleoside analogs from their prodrug form to 
their active form, where dNKs are responsible for the first step. The present studies 
with Ba-TK and Ba-TMPK have revealed that the enzymes have similar substrate 
preferences with leads in the 2’-arabinosyl position and possibly in the 5-position 
on the base (figure 8). The phosphorylated products from the TK reaction will then 
be further phosphorylated by the TMPK avoiding accumulation. Ba-TMPK is also 
the site where the salvage and the de novo synthesis meet in nucleotide synthesis 
and therefore is a potential target for non-substrate analogs. Blocking TMPK will 
in turn stop both pathways to dTTP synthesis that will eventually lead to cell 
death.  
 
Figure 8 summarizes the substrate analog specificity of Uu-TK, Ba-TK and Ba-
TMPK, respectively. Except the position preferences mentioned above Uu-TK and 
Ba-TK also tolerate substitutions at the 3’-position. Additionally, Uu-TK accepts 
modifications at the 2’-arabinosyl position. These substitution differences are 
interesting and should be investigated further. They will also be helpful in finding 
and developing new substrate analogs and inhibitors for the three enzymes in 
question. 
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The results of the present studies have given a deeper structural and functional 
understanding of enzymes in the thymidylate synthesis. The acquired knowledge 
will aid in defining the differences and similarities in thymidylate synthesis and be 
of value in future drug design. 
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Figure 8. (A) Uu-TK (B) Ba-TK and (C) Ba-TMPK activity of substrate analogs. The 
arrows indicate the modifications and the percentage values are the enzyme activity with 
100 μM substrate analog as compared to that with dTMP (= 100%). In (C) the substrate 
analog concentration was 1 mM and the three other values represent the enzyme efficiency 
(kcat/Km) as compared to that with dTMP.  
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Conclusions 
  Uu-TK and Ba-TK are strictly pyrimidine specific and regarding their analog 
specificity: 5-Halogenated analogs give the highest activity. Modifications at 
the 3-position on the base give moderate activities while 3’-analogs in general 
have a higher activity. 2’-analogs are essentially not substrates but a fluorine 
substitution at the 2’-arabinosyl position is accepted. 
 
  Uu-TK and Ba-TK can use all nucleoside triphosphates as phosphate donors 
except dTTP, which is a very poor phosphate donor for Ba-TK and a feedback 
inhibitor for Uu-TK. 
 
  The Uu-TK structure, i.e. a TK1 enzyme structure, is unique, containing a long 
loop and a structural zinc ion - the lasso domain. The core structures of TK1 
enzymes resemble an ATPase family and are not related to the other dNKs.  
 
  Ba-TMPK is a thymidylate specific kinase and uses ATP or dATP as phosphate 
donors. 
 
  FMAUMP is a good substrate for Ba-TMPK and its nucleoside form is a potent 
inhibitor. FMAU(MP) may thus serve as a lead for future design of antibiotics 
against B. anthracis. 
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